Ter Heine Rob, Frederix Geert Wj, Geenen Joost W, Hövels Anke M, van Vulpen Marco, Kooistra Anko, De Klerk John Mh, Bloemendal Haiko J
Radboudumc, Department of Pharmacy, Geert Grooteplein-Zuid 22, 6525 GA, Nijmegen, The Netherlands.
Julius Center for Health Sciences & Primary Care, University Medical Center, Universiteitsweg 100, 3584 CG Utrecht, The Netherlands.
J Comp Eff Res. 2017 Oct;6(7):575-581. doi: 10.2217/cer-2017-0026. Epub 2017 Sep 13.
To assess the resource use and associated costs of treating patients with metastatic prostate cancer with a focus on skeletal-related events (SREs).
We performed a bottom-up cost of illness study in The Netherlands.
A total of 136 patients were studied. The mean total costs were €17,931 per patient. SREs that required hospitalization (n = 53) were, at median costs of €2039-9346, depending on care. These SREs had median costs of €200-1912.
Our data provide a basis to investigate the cost-effectiveness of novel treatment options for metastatic prostate cancer. The impact of SREs on total costs could justify policy aimed at actively preventing SREs, possibly resulting in better quality of life and cost-reduction.
评估转移性前列腺癌患者的资源使用情况及相关治疗成本，重点关注骨相关事件（SREs）。
我们在荷兰开展了一项自下而上的疾病成本研究。
共研究了136例患者。每位患者的平均总成本为17,931欧元。需要住院治疗的SREs（n = 53），根据护理情况，中位数成本为2039 - 9346欧元。这些SREs的中位数成本为200 - 1912欧元。
我们的数据为研究转移性前列腺癌新治疗方案的成本效益提供了依据。SREs对总成本的影响可为旨在积极预防SREs的政策提供正当理由，这可能会带来更好的生活质量并降低成本。
